Design, synthesis, and molecular docking studies of benzimidazole‐1,3,4‐triazole hybrids as carbonic anhydrase I and II inhibitors
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von İsmail Çelik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey. Hauptthemen laut MEDLINE: Carbonic Anhydrase I, Carbonic Anhydrase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
In this study, with an aim to develop novel heterocyclic hybrids as potent enzyme inhibitors, we synthesized a series of 10 novel 2‐(4‐(4‐ethyl‐5‐(2‐(substitutedphenyl)‐2‐oxo‐ethylthio)‐4 H ‐1,2,4‐triazol‐3‐yl)‐phenyl)‐5,6‐dimethyl‐1 H ‐benzimidazole ( 5a–5j ) derivatives and characterized by 1 H‐NMR, 13 C‐NMR, and HRMS. These compounds were evaluated for their inhibitory activity against hCA I and hCA II. All the compounds exhibited good hCA I and hCA II inhibitory activities with IC 50 values in range of 1.288 μM–3.122 μM. Among all these compounds, compound 5e, with an IC 50 value of 1.288 μM is the most active against carbonic hCA I. Compound 5h with an IC 50 value of 1.532 μM is the most active against carbonic hCA‐II. Compounds 5a–5j were also evaluated for their cytotoxic effects on the L929 mouse fibroblast (normal) cell line. The compounds were also analyzed for their antioxidant capacity by TAS, FRAP, and DPPH activity. Enzyme inhibition kinetics showed all compounds 5a – 5j to inhibit the enzyme by non‐competitive. The most active compound 5e for hCA I and compound 5h for hCA‐II were subjected to molecular docking, which revealed their binding interactions with the enzyme's active site, confirming the experimental findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Selçuk University, Konya, Turkey.
- Department of Food Technology, ErzurumVocational Training School, Ataturk University, Erzurum, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Turkey.
- Department of Biochemistry, Faculty of Science, Selçuk University, Konya, Turkey.
ORCID-Profile: İsmail Çelik, Ulviye Acar Çevik
Zitieren
APA
Çelik, İ., Acar Çevik, U., Küçükoğlu, K., Nadaroglu, H., Bostancı, H. E., Işık, A., Özkay, Y., & Kaplancıklı, Z. A. (2024). Design, synthesis, and molecular docking studies of benzimidazole‐1,3,4‐triazole hybrids as carbonic anhydrase I and II inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14351
Vancouver
Çelik İ, Acar Çevik U, Küçükoğlu K, Nadaroglu H, Bostancı HE, Işık A, et al. Design, synthesis, and molecular docking studies of benzimidazole‐1,3,4‐triazole hybrids as carbonic anhydrase I and II inhibitors. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14351
BibTeX
@article{elik2024,
author = {Çelik, İsmail and Acar Çevik, Ulviye and Küçükoğlu, Kaan and Nadaroglu, Hayrunnisa and Bostancı, Hayrani Eren and Işık, Ayşen and Özkay, Yusuf and Kaplancıklı, Zafer Asım},
title = {Design, synthesis, and molecular docking studies of benzimidazole‐1,3,4‐triazole hybrids as carbonic anhydrase I and II inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14351}
}
EUVIMED